Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540008 | 0.79 | LTA4H (0.56) | LTA4HMTNR1AMTNR1BGPR55CYP11B1 | |
| SCHEMBL5421590 | 0.77 | LTA4H (0.58) | LTA4HMTNR1AMTNR1BGPR55CYP11B1 | |
| SCHEMBL3300286 | 0.77 | LTA4H (0.58) | LTA4HMTNR1AMTNR1BGPR55ALDH1A1 | |
| SCHEMBL11288852 | 0.77 | LTA4H (0.58) | LTA4HMTNR1AMTNR1BGPR55ALDH1A1 | |
| SCHEMBL7116653 | 0.76 | MTNR1A (0.62) | LTA4HMTNR1AMTNR1BGPR55CYP11B1 | |
| SCHEMBL21227008 | 0.76 | LTA4H (0.56) | LTA4HMTNR1AMTNR1BGPR55CYP11B1 | |
| SCHEMBL9446226 | 0.76 | LTA4H (0.56) | LTA4HMTNR1AMTNR1BGPR55CYP11B1 | |
| SCHEMBL31651461 | 0.76 | MEN1 (0.57) | LTA4HMTNR1AMTNR1BGPR55HSP90AA1 | |
| SCHEMBL5188864 | 0.76 | LTA4H (0.56) | LTA4HMTNR1AMTNR1BGPR55CYP11B1 | |
| SCHEMBL9818379 | 0.76 | LTA4H (0.56) | LTA4HMTNR1AMTNR1BGPR55CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | LTA4H 364/4885MTNR1A 3571/4885MTNR1B 3656/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | LTA4H 423/4885MTNR1A 3524/4885MTNR1B 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.